Central Nervous System Therapeutics Market Expected to Achieve 8.9% CAGR by 2029: Growth Forecast Insights

Use code ONLINE30 to get 30% off on global market reports and stay ahead of tariff changes, macro trends, and global economic shifts.

How Large Will the Central Nervous System Therapeutics Market Size By 2025?
Recent years have shown robust growth in the central nervous system therapeutics market size. It's expected to expand from $123.53 billion in 2024 to $134.99 billion in 2025, demonstrating a compound annual growth rate (CAGR) of 9.3%. Factors contributing to the robust growth during the historical period include a spike in neurological disorders, heightened awareness of mental health, increased research and development activities, higher demand for personalized medicine, and a surge in trade agreements.

How Big Is the Central Nervous System Therapeutics Market Size Expected to Grow by 2029?
The market size for central nervous system therapeutics is predicted to witness robust growth in the coming few years. The market is expected to reach $190.07 billion in 2029 with a compound annual growth rate (CAGR) of 8.9%. The growth during this period can be credited to the expanding prevalence of CNS disorders, heightened focus on creating therapeutics, increased occurrence of Alzheimer's disease, aging population growth, and escalating demand for effective treatments. Key trends during this projection period encompass the use of artificial intelligence in diagnostics, progress in the creation of antidepressant medicines, drug delivery systems, advances in neurology, and the identification of biomarkers.

View the full report here:
https://www.thebusinessresearchcompany.com/report/central-nervous-system-therapeutics-global-market-report

Which Key Market Drivers Powering Central Nervous System Therapeutics Market Expansion and Growth?
The surge in mental health disorders is anticipated to boost the central nervous system therapeutics market expansion. Mental health disorders, encompassing conditions such as depression, anxiety disorders, schizophrenia, and bipolar disorder, impact an individual's thought processes, emotions, behaviors, and mood. This growing prevalence is stimulated by heightened exposure to chronic stress, which can compromise emotional control, diminish coping strategies, and lead to issues, including anxiety, depression, and burnout. Therapeutics for the Central Nervous System (CNS) address mental health disorders by focusing on brain compounds and neural pathways responsible for mood, behavior, and cognition. For example, in a report from December 2025, issued by Bristol City Council, a local government body based in the UK, it was reported that 66,815 patients who were aged 18 and over in Bristol were listed on GP depression registers in 2022/23. This signifies a 6.0% increase from 2021/22. Consequently, the rising prevalence of mental health disorders fuels the expansion of the central nervous system therapeutics market.

Get your free sample here:
https://www.thebusinessresearchcompany.com/sample.aspx?id=27249&type=smp

What Are the Key Trends Driving Central Nervous System Therapeutics Market Growth?
In the central nervous system therapeutic market, important businesses are concentrating their efforts on creating cutting-edge techniques like capsid engineering. This approach aims to increase targeted gene delivery, therapeutic effectiveness and penetration of the blood-brain barrier, leading to improved neurological disorder therapies. Capsid engineering involves altering and optimizing the protein shell (capsid) of viral vectors, primarily adeno-associated viruses (AAVs), employed in gene therapy. For instance, Coave Therapeutics S.A., a biotech firm located in France, introduced in May 2025 their novel adeno associated virus (AAV) coAAV CSF 01 for central nervous system (CNS) delivery using their unique ALIGATER platform. The product showed considerable boosts in transduction efficiency and safety compared to AAV9. Notably, when applied through intracisternal magna and intracerebroventricular methods, the coAAV-CSF-01 displayed 100 times and 10,000 times higher transgene expression in the cortex and the hippocampus respectively, at the same dosage. Moreover, the same expression levels as AAV9 were achieved at only a fifth of the dose, underlining its higher potency. On top of that, the vector exhibited much lower off-target expression in peripheral organs like the liver while keeping a positive safety profile, including the preservation of peripheral nerve integrity. These factors highlight the vector's ability to boost CNS gene therapy results with better accuracy and reduced systemic risk.

What Are the Emerging Segments in the Central Nervous System Therapeutics Market?
The central nervous system therapeutics market covered in this report is segmented

1) By Drug Class: Anesthetics, Anticonvulsants, Antiemetics, Central Nervous System (CNS) Stimulants, Pain Relievers, Other Drug Classes
2) By Disease: Neurovascular Diseases, Mental Health, Degenerative Disorders, Genetic Diseases, Substance Abuse Disorders, Autoimmune And Inflammatory Diseases, Central Nervous System (CNS) Trauma, Infectious Diseases, Central Nervous System (CNS) Cancer, Other Diseases
3) By Distribution Channel: Hospital Pharmacies, Retail Pharmacies, Other Distribution Channels
4) By Application: Hospital, Clinic, Homecare, Other Applications

Subsegments:
1) By Anesthetics: General Anesthetics, Local Anesthetics, Dissociative Anesthetics, Inhalation Anesthetics, Intravenous Anesthetics
2) By Anticonvulsants: Sodium Channel Blockers, GABA Enhancers, Calcium Channel Blockers, SV2A Modulators, Mixed Mechanism Agents
3) By Antiemetics: Serotonin 5-HT3 Antagonists, Dopamine Antagonists, Neurokinin-1 (NK1) Receptor Antagonists, Antihistamines, s
4) By Central Nervous System (CNS) Stimulants: Amphetamines, Methylphenidates, Modafinil and Armodafinil, Caffeine-Based Stimulants, Xanthine Derivatives
5) By Pain Relievers: Opioid Analgesics, Non-Steroidal Anti-Inflammatory Drugs (NSAIDs), Antidepressants for Neuropathic Pain, Anticonvulsants for Pain Relief, Topical Agents
6) By Other Drug Classes: Antipsychotics, Antidepressants, Muscle Relaxants, Sedatives and Hypnotics, Neuroprotective Agents

Tailor your insights and customize the full report here:
https://www.thebusinessresearchcompany.com/customise?id=27249&type=smp

Who Are the Global Leaders in the Central Nervous System Therapeutics Market?
Major companies operating in the central nervous system therapeutics market are Biogen Inc., Otsuka Pharmaceutical Co Ltd., UCB S.A., Jazz Pharmaceuticals plc, Supernus Pharmaceuticals Inc., Biohaven Ltd., Acadia Pharmaceuticals Inc., Neumora Therapeutics Inc., Cerevel Therapeutics LLC, Axsome Therapeutics Inc., TauRx Therapeutics Ltd., Kyverna Therapeutics Inc., Immunic Inc., LEXEO Therapeutics Inc., Autobahn Therapeutics, BrainStorm Cell Therapeutics Inc., Progentos Therapeutics Inc., Tonix Pharmaceuticals Holding Corp., Neuroplast B.V., and Assertio Holdings Inc.

Which are the Top Profitable Regional Markets for the Central Nervous System Therapeutics Industry?
North America was the largest region in the central nervous system therapeutics market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the central nervous system therapeutics market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Purchase the full report today:
https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=27249

This Report Supports:
1.Business Leaders & Investors - To identify growth opportunities, assess risks, and guide strategic decisions.
2.Manufacturers & Suppliers - To understand market trends, customer demand, and competitive positioning.
3.Policy Makers & Regulators - To track industry developments and align regulatory frameworks.
4.Consultants & Analysts - To support market entry, expansion strategies, and client advisory work.

Speak With Our Expert:
Saumya Sahay
Americas +1 310-496-7795,
Asia +44 7882 955267 & +91 8897263534,
Europe +44 7882 955267
Email: saumyas@tbrc.info
The Business Research Company - www.thebusinessresearchcompany.com

Follow Us On:
LinkedIn: https://in.linkedin.com/company/the-business-research-company

Learn More About The Business Research Company
With over 15,000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Our flagship product, the Global Market Model delivers comprehensive and updated forecasts to support informed decision-making.

This release was published on openPR.